Abarceo AB has developed new voltage-dependent anion-selective channel protein 1 (VDAC1) inhibitors reported to be useful for the treatment of diabetes type 1 and 2.

A recent Merck Sharp & Dohme LLC patent details new substituted isoquinoline derivatives acting as tyrosine-protein phosphatase non-receptor type 1 (PTPN1; PTP-1B) and/or PTPN2 (TCPTP) inhibitors potentially useful for the treatment of cancer.

Work at Childrens Medical Center Corp. has led to the identification of new gasdermin-D (GSDMD) activators reported to be useful for the treatment of cancer.

Amgen Inc. has patented indazole-containing compounds acting as GTPase KRAS (G12D mutant) inhibitors potentially useful for the treatment of cancer.

Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.

A Black Diamond Therapeutics Inc. patent describes new alkyne-substituted quinazoline derivatives acting as EGFR (HER1; erbB1) inhibitors particularly, EGFR mutant inhibitors, potentially useful for the treatment of cancer.

Biosplice Therapeutics Inc. has prepared and tested 4-alkoxypyrrolo[2,1-F][1,2,4]triazines acting as dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A) inhibitors potentially useful for the treatment of Alzheimer’s disease.

Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful for the treatment of psychiatric disorders.

Pfizer Inc. has identified signal transducer and activator of transcription 6 (STAT6) inhibitors reported to be useful for the treatment of Alzheimer’s disease, cancer, atherosclerosis, metabolic dysfunction-associated steatohepatitis, respiratory and dermatological disorders.

AGC Inc. has synthesized compounds acting as prostaglandin E2 receptor EP4 subtype (PTGER4; EP4) antagonists reported to be useful for the treatment of cancer.